Molecular mechanism of biased signaling at the kappa opioid receptor

• Published in: Nature communications Vol. 14; no. 1; p. 1338
• Main Authors: El Daibani, Amal, Paggi, Joseph M, Kim, Kuglae, Laloudakis, Yianni D, Popov, Petr, Bernhard, Sarah M, Krumm, Brian E, Olsen, Reid H J, Diberto, Jeffrey, Carroll, F Ivy, Katritch, Vsevolod, Wünsch, Bernhard, Dror, Ron O, Che, Tao
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 11.03.2023; Nature Publishing Group UK; Nature Portfolio
• Subjects: Addictions; Agonists; Analgesics, Opioid; Arrestin; Arrestin - metabolism; Atomic structure; Bias; Crystal structure; Drug abuse; G protein-coupled receptors; GTP-Binding Proteins - metabolism; Molecular dynamics; Molecular modelling; Molecular structure; Morphinans; Mutagenesis; Narcotics; Opioid receptors (type kappa); Pain; Pain management; Proteins; Receptors; Receptors, Opioid, kappa - metabolism; Science & Technology - Other Topics; Side effects; Signaling; Simulation; Therapeutic targets
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-023-37041-7

The κ-opioid receptor (KOR) has emerged as an attractive drug target for pain management without addiction, and biased signaling through particular pathways of KOR may be key to maintaining this benefit while minimizing side-effect liabilities. As for most G protein-coupled receptors (GPCRs), however, the molecular mechanisms of ligand-specific signaling at KOR have remained unclear. To better understand the molecular determinants of KOR signaling bias, we apply structure determination, atomic-level molecular dynamics (MD) simulations, and functional assays. We determine a crystal structure of KOR bound to the G protein-biased agonist nalfurafine, the first approved KOR-targeting drug. We also identify an arrestin-biased KOR agonist, WMS-X600. Using MD simulations of KOR bound to nalfurafine, WMS-X600, and a balanced agonist U50,488, we identify three active-state receptor conformations, including one that appears to favor arrestin signaling over G protein signaling and another that appears to favor G protein signaling over arrestin signaling. These results, combined with mutagenesis validation, provide a molecular explanation of how agonists achieve biased signaling at KOR.